|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 214.35 USD | -1.11% |
|
-2.60% | -6.19% |
| 06:52am | Genmab's Phase 3 Study with Epcoritamab Fails to Meet Overall Survival Endpoint | FW |
| 04:39am | Genmab's Epcoritamab Improves Progression-free Survival in Lymphoma Patients, Phase 3 Data Shows | MT |
Quotes 5-day view: AbbVie Inc.
Delayed Quote Nyse| 13/01/2026 | 14/01/2026 | 15/01/2026 | 16/01/2026 | 16/01/2026 | |
|---|---|---|---|---|---|
| Last | 220.75 $ | 221.89 $ | 216.75 $ | 214.35 $ | 214.35 $ |
| Volume | 4,872,602 | 8,426,842 | 6,954,243 | 8,649,746 | 8,649,746 |
| Change | +0.32% | +0.52% | -2.32% | -1.11% | -1.11% |
| Opening | 219.53 $ | 221.00 $ | 222.52 $ | 215.61 $ | 215.61 $ |
| High | 220.75 $ | 223.34 $ | 223.03 $ | 217.34 $ | 217.34 $ |
| Low | 215.85 $ | 217.00 $ | 215.83 $ | 213.88 $ | 213.88 $ |
Performance
| 1 day | -1.11% | ||
| 1 week | -2.60% | ||
| Current month | -6.19% | ||
| 1 month | -3.80% | ||
| 3 months | -6.63% | ||
| 6 months | +13.26% | ||
| Current year | -6.19% | ||
| 1 year | +24.94% | ||
| 3 years | +43.67% | ||
| 5 years | +93.95% | ||
| 10 years | +273.82% |
Volumes
marketsDaily volume
8,649,746
Estimated daily volume
14,918,851
Avg. Volume 20 sessions
6,642,365
Daily volume ratio
2.25
Avg. Volume 20 sessions USD
1,423,790,937.75
Record volume 1
122,740,900
Record volume 2
90,131,820
Record volume 3
61,236,800
Capital turnover ratio
0
Float rotation
0
Basic data
Capitalization (USD)
378,838,895,869
Net sales (USD)
56,334,000,000
Number of employees
55,000
Sales / Employee (USD)
1,024,255
Free-Float
96.39 %
Free-Float capitalization (USD)
378,415,048,324
Average Daily Capital Traded
0.38%
Indicators
Moving average 5 days
218.76
Moving average 20 days
225.5
Moving average 50 days
226.2
Moving average 100 days
224.53
Price spread / (MMA5)
+2.06%
Price spread / (MMA20)
+5.20%
Price spread / (MMA50)
+5.53%
Price spread / (MMA100)
+4.75%
STIM
RSI 9 days
36.24
RSI 14 days
39.78
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.11% | -2.60% | +24.94% | +43.67% | 379B | ||
| +0.53% | -2.37% | +43.09% | +194.99% | 930B | ||
| -0.41% | +6.98% | +48.72% | +28.81% | 527B | ||
| -0.60% | +1.26% | +29.94% | +17.78% | 371B | ||
| -1.15% | -1.63% | +28.68% | +21.63% | 292B | ||
| -0.03% | +1.51% | +29.51% | +36.74% | 276B | ||
| -1.93% | -1.54% | +11.14% | +0.04% | 270B | ||
| -2.92% | -0.41% | -31.52% | -21.19% | 268B | ||
| +0.12% | +1.32% | +21.43% | +24.97% | 178B | ||
| +3.01% | +3.15% | +36.01% | +49.16% | 155B | ||
| Average | -0.48% | +0.95% | +24.19% | +39.66% | 364.59B | |
| Weighted average by Cap. | -0.45% | +0.62% | +29.28% | +66.50% |
Historical Quotes: AbbVie Inc.
| Date | Opening | High | Low | End-of-day | Volume | Change |
|---|
Latest transactions
80c53675bad2a679da20bf996942c.XHSTQKp4unUeOWUhKamJ27yXf4evDmufOCQALRc3Pt4.KgzYNMgdyRN3AVUQHfDtl9qkKvDbOl76D0E5elZOaI0qQMoF-An2TSxsNA
| Date | Price | Volume | Total |
|---|---|---|---|
| 21:00:02 | 214.35 | 1,147,944 | 4,079,577 |
| 21:00:00 | 214.33 | 100 | 2,931,633 |
| 21:00:00 | 214.34 | 100 | 2,931,533 |
| 20:59:59 | 214.32 | 176 | 2,931,433 |
| 20:59:59 | 214.33 | 100 | 2,931,257 |
| 20:59:59 | 214.33 | 100 | 2,931,157 |
| 20:59:59 | 214.34 | 291 | 2,931,057 |
| 20:59:59 | 214.35 | 149 | 2,930,766 |
| 20:59:59 | 214.35 | 500 | 2,930,617 |
| 20:59:59 | 214.35 | 137 | 2,930,117 |
Course Extremes
| 1 week | 213.88 | 223.34 | |
| 1 month | 213.88 | 237.04 | |
| Current year | 213.88 | 237.04 | |
| 1 year | 164.39 | 244.81 | |
| 3 years | 130.96 | 244.81 | |
| 5 years | 101.81 | 244.81 | |
| 10 years | 51.6 | 244.81 |
Monthly variations
Annual variations
| 2026 | -6.19% | ||
| 2025 | +28.58% | ||
| 2024 | +14.67% | ||
| 2023 | -4.11% | ||
| 2022 | +19.36% | ||
| 2021 | +26.36% | ||
| 2020 | +21.02% | ||
| 2019 | -3.96% | ||
| 2018 | -4.67% | ||
| 2017 | +54.44% | ||
| 2016 | +5.71% | ||
| 2015 | -9.47% | ||
| 2014 | +23.92% | ||
| 2013 | +54.60% | ||
| 2012 | -2.40% |
- Stock Market
- Equities
- ABBV Stock
- Quotes AbbVie Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















